{"pub": "reuters", "url": "https://uk.reuters.com/article/uk-gsk-divestiture-bavarian-nordic/gsk-to-sell-two-travel-vaccines-to-danish-biotech-firm-idUKKBN1X00MN", "downloaded_at": "2019-10-21 07:38:00.062921+00:00", "title": "GSK to sell two travel vaccines to Danish biotech firm", "language": "en", "text": "FILE PHOTO: The GlaxoSmithKline (GSK) logo is seen on top of GSK Asia House in Singapore, March 21, 2018. REUTERS/Loriene Perera/File Photo\n\n(Reuters) - GlaxoSmithKline Plc said on Monday it will sell two travel vaccines to Denmark-based biotechnology company Bavarian Nordic for an upfront payment of 301 million euros ($335.71 million).\n\nThe sale of anti-rabies treatment Rabipur and Encepur, used for the prevention of tick-borne encephalitis, by the British drugmaker includes milestone payments of up to 495 million euros.", "description": "GlaxoSmithKline Plc said on Monday it will sell two travel vaccines to Denmark-based biotechnology company Bavarian Nordic for an upfront payment of 301 million euros ($335.71 million).", "authors": ["Reuters Editorial", "Min Read"], "top_image": "https://s2.reutersmedia.net/resources/r/?m=02&d=20191021&t=2&i=1443262274&w=1200&r=LYNXMPEF9K0ED", "published_at": "2019-10-21"}